Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis

The phase 3 ENLIGHTEN program will consist of 2 phase 3 trials evaluating the safety and efficacy of pegozafermin in patients with MASH.

Related Keywords

,Hank Mansbach ,Rohit Loomba ,Uc San Diego Health Rohit Loomba ,Drug Administration ,Diego Health ,California San Diego School ,Breakthrough Therapy Designation ,Chief Medical Officer ,Initiates Phase ,Fibrosis Trial ,Granted Breakthrough Therapy Designation ,Nonalcoholic Steatohepatitis ,Shows Sustained Benefit ,